Drug intelligence / Profile preview

HMR code 24-001

Development stage: Unknown
Lead developer: Nxera Pharma

Overview

HMR code 24-001 is a clinical trial protocol identifier for a Phase I clinical study sponsored by Nxera Pharma UK Limited (formerly Sosei Heptares) in healthy human volunteers. The trial is designed as a randomized, placebo-controlled crossover MRI interventional study utilizing a caffeine challenge to evaluate neuroimaging metrics. Because the trial is registered under a deferred publication scheme, the specific identity, chemical structure, and mechanism of action of the investigational drug being evaluated remain confidential and have not been publicly disclosed.

Beyond the preview

Go deeper on HMR code 24-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HMR code 24-001.

Explore the full profile